A large-scale study indicates that GLP-1 receptor agonists could offer protective benefits against fractures in older type 2 diabetes patients, though further trials are needed to confirm the findings.
Medications in the GLP-1 class, best known for treating diabetes and aiding weight loss, may also help protect against fractures in older adults with type 2 diabetes, according to research reported by Euronews. The analysis drew on medical records for more than 133,000 Americans aged 50 to 90 who were diagnosed with type 2 diabetes between 2015 and 2022, and compared people taking GLP-1 drugs with patients prescribed DPP-4 medicines.
The findings suggested a 21% lower risk of fractures caused by minor trauma among those using GLP-1 treatments. The strongest differences were seen in spinal fractures, where the risk was 32% lower, and in hip or femur fractures, where the reduction was 30%. Researchers said the association remained even after accounting for changes in body weight and blood sugar, which points to the possibility that these medicines may influence bone health directly rather than only through weight loss or improved glucose control.
That would be notable because people with type 2 diabetes are paradoxically more likely to break bones even when bone density appears normal or above average. Specialists often attribute that to poorer bone quality and internal structural changes rather than to density alone. The new findings also fit with a growing body of research. A 2025 systematic review and meta-analysis indexed in PubMed found no significant increase in fracture risk with GLP-1 receptor agonists, while noting improvements in lumbar spine and hip-neck bone mineral density and calling for better clinical trials.
Still, the authors of the new study urged caution. Because it was an observational analysis of medical records, it cannot prove that GLP-1 drugs directly reduced fracture risk, and other factors such as physical activity, muscle mass or pre-existing bone strength could have influenced the outcome. The study also did not find the same protective signal in people taking GLP-1 medicines solely for weight loss without type 2 diabetes. Further controlled trials will be needed to determine whether the effect is real, how durable it may be and whether it applies across longer treatment periods. Recent research published in JAMA Network Open in July 2026 also pointed to a lower fragility fracture risk after GLP-1 initiation, though the benefit appeared to weaken over time.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
